Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 57 of 1542 for:    Androgens

ODM-201 vs Androgen Deprivation Therapy in Hormone naïve Prostate Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02972060
Recruitment Status : Recruiting
First Posted : November 23, 2016
Last Update Posted : April 25, 2018
Sponsor:
Collaborator:
Bayer
Information provided by (Responsible Party):
European Organisation for Research and Treatment of Cancer - EORTC

Brief Summary:

This is an open label non-comparative controlled randomized phase II study. The experimental arm is the group receiving ODM-201. The group receiving androgen-deprivation therapy (ADT) is included as an internal control.

The primary trial objective is to demonstrate that ODM-201 produces prostate-specific antigen (PSA) response rates at 24 weeks (defined as ≥80% reduction compared to baseline) that are in the range of those achieved with 24 weeks of ADT.

In total, this 1:1 randomized study will therefore require randomization of at least 250 patients, 125 to each arm.


Condition or disease Intervention/treatment Phase
Prostate Cancer Drug: ODM-201 Drug: ADT Phase 2

Detailed Description:

ODM 201 will be administered as oral 300-mg tablets. The dose of study drug to be administered is 600 milligrams (mg) (2 x 300-mg tablets) twice daily (bid) for a daily dose of 1200 mg. It is recommended that ODM-201 be taken with food.

Subjects who have clinical benefit at week 24 may continue to receive ODM-201 at the discretion of the investigator until disease progression, objective or clinical, or occurrence of an unacceptable toxicity. This includes those that will receive external beam radiation therapy.

Any anti-cancer therapy other than the study drug given as single agent will not be considered part of the protocol treatment.

The standard treatment for this stage of the disease is androgen deprivation therapy (ADT) by means of Luteinizing hormone-releasing hormone (LHRH) antagonist for 24 weeks or by LHRH agonist therapy for 24 weeks with 4 weeks of anti-androgen to prevent flare.

This includes leuprolide, goserelin, triptorelin, and degarelix. Beyond week 24, the treatment will be left to the discretion of the treating physician.

The primary trial objective is to demonstrate that ODM-201 produces prostate-specific antigen (PSA) response rates at 24 weeks (defined as ≥80% reduction compared to baseline) that are in the range of those achieved with 24 weeks of ADT.

The secondary objectives are to:

  • To document the effects of ODM-201 compared to ADT in terms of patient-reported side effects of hormonal therapy, based on the Hormonal treatment (HTR) symptom scale of EORTC QLQ PR25 at 24 weeks;
  • To document the effects of ODM-201 compared to ADT in terms of patient-reported side effects of hormonal therapy, based on EORTC QLQ C30 and PR25 at 24 weeks;
  • To document the effect of ODM-201 on PSA complete response at 24 weeks (defined as ≥ 90% reduction from baseline);
  • To document the effect of ODM-201 on objective response rate at 24 weeks in patients with RECIST 1.1 measurable disease at baseline;
  • To document the safety and tolerability of ODM-201 vs. ADT in subjects who have not previously received hormone treatment for prostate cancer;
  • To document the effects of ODM-201 on androgen deprivations symptoms using the Aging male symptoms (AMS) questionnaires;
  • To document the proportion of patients who opted to continue treatment with ODM-201 beyond the protocolized 24 weeks

The primary endpoint is the PSA response assessed at 24 weeks. PSA response is defined as a ≥ 80% decline in PSA measurement taken at week 24 relative to the measurement taken at baseline, in the ODM-201 study arm. The ADT arm is used as an internal control.

Key secondary endpoints:

  • Change in hormone-treatment related symptoms scale of the EORTC QLQ-PR25 at 24 weeks compared to baseline in the ODM-201 study arm. A 10-point difference is regarded as a clinically meaningful benefit.
  • Objective response rate at 24 weeks in patients with RECIST 1.1 measurable disease at baseline
  • PSA response at 24 weeks defined as a ≥90% decline in PSA compared to baseline
  • Safety according to National Cancer Institute - Common terminology for adverse events (NCI-CTC) version 4.0

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 250 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2 Randomized Open-Label Study of Oral ODM-201 vs. Androgen Deprivation Therapy (ADT) With LHRH Agonists or Antagonist in Men With Hormone Naive Prostate Cancer
Actual Study Start Date : December 1, 2017
Estimated Primary Completion Date : December 2020
Estimated Study Completion Date : May 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: ADT

The standard treatment for this stage of the disease is ADT by means of LHRH antagonist for 24 weeks or by LHRH agonist therapy for 24 weeks with 4 weeks of anti-androgen to prevent flare.

This includes leuprolide, goserelin, triptorelin, and degarelix. Beyond week 24, the treatment will be left to the discretion of the treating physician.

Drug: ADT

ADT by means of LHRH antagonist for 24 weeks or by LHRH agonist therapy for 24 weeks with 4 weeks of anti-androgen to prevent flare.

This includes leuprolide, goserelin, triptorelin, and degarelix. Beyond week 24, the treatment will be left to the discretion of the treating physician.


Experimental: ODM 201

ODM 201 will be administered as oral 300-mg tablets. The dose of study drug to be administered is 600 mg (2 x 300-mg tablets) bid for a daily dose of 1200 mg. It is recommended that ODM-201 be taken with food.

Subjects who have clinical benefit at week 24 may continue to receive ODM-201 at the discretion of the investigator until disease progression, objective or clinical, or occurrence of an unacceptable toxicity. This includes those that will receive external beam radiation therapy.

Any anti-cancer therapy other than the study drug given as single agent will not be considered part of the protocol treatment.

Drug: ODM-201
ODM-201 is a novel, oral, potent nonsteroidal AR inhibitor. ODM 201 will be administered as oral 300-mg tablets. The dose of study drug to be administered is 600 mg (2 x 300-mg tablets) b.i.d. to a daily dose of 1200 mg. It is recommended that ODM-201 be taken with food. Treatment should be initiated within 28 days from randomization.




Primary Outcome Measures :
  1. PSA response [ Time Frame: 24 weeks ]
    PSA response is defined as a ≥ 80% decline in PSA measurement taken at week 24 relative to the measurement taken at baseline, in the ODM-201 study arm. The ADT arm is used as an internal control.


Secondary Outcome Measures :
  1. EORTC QLQ-PR25 [ Time Frame: 24 weeks ]
    Change in hormone-treatment related symptoms scale of the EORTC QLQ-PR25 at 24 weeks compared to baseline in the ODM-201 study arm. A 10-point difference is regarded as a clinically meaningful benefit.

  2. Objective tumor response [ Time Frame: 24 weeks ]
    Objective response rate at 24 weeks in patients with RECIST 1.1 measurable disease at baseline

  3. 90% PSA response rate [ Time Frame: 24 weeks ]
    PSA response at 24 weeks defined as a ≥90% decline in PSA compared to baseline

  4. evaluation of safety [ Time Frame: The collection period will start from randomization until 30 days after last protocol treatment administration. ]
    All adverse events will be recorded; the investigator will assess whether those events are drug related (reasonable possibility, no reasonable possibility) and this assessment will be recorded in the database for all adverse events.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically confirmed prostate cancer (all stages) for whom continuous androgen-deprivation therapy (ADT) is indicated for a minimum period of 24 weeks
  • Patient presenting with a maximum of 4 confirmed metastatic lesions, including bone, extra-pelvic lymph nodes, and pelvic lymph nodes > 2 cm on baseline Computed tomography(CT) or Magnetic resonance imaging (MRI) and/or Tc bone scintigraphy. Visceral metastases are excluded
  • Asymptomatic for metastatic prostate cancer; urinary symptoms are allowed
  • Baseline testosterone ≥ 8 nmol/L or 230 ng/dL
  • Two subsequent PSA values ≥ 2 ng/ml, taken at minimum 2-week interval, with the second being equal to or higher than the first one
  • WHO performance status (PS) of 0-1
  • G8 score ≥ 14 for patients aged ≥ 70 years old
  • A life expectancy of at least 12 months
  • Able to swallow the study drug and comply with the study requirements
  • Adequate bone marrow function (absolute neutrophil count (ANC) ≥ 1.5 10exp9/L; hemoglobin ≥ 10.0 g/dl, platelets ≥ 100 10exp9/L)
  • Adequate renal function: creatinine clearance/eGFR within normal limits to baseline assessed as per local standard method
  • Albumin > 25 g/L
  • Adequate hepatic function:

Bilirubin: total bilirubin ≤ to 1.5 X upper limit of normal (ULN)

  • Aspartate aminotransferase (AST) and/or Alanine aminotransferase(ALT) ≤ 2.5 X ULN
  • Normal cardiac function according to local standard by 12-lead Electrocardiogram (ECG) (complete, standardized 12-lead recording)
  • Before patient registration/randomization, written informed consent must be given according to International Conference on Harmonization on Good Clinical Practices (ICH/GCP), and national/local regulations.

Exclusion Criteria:

  • any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule
  • Previously or currently receiving hormonal therapy with intent to treat prostate cancer disease (surgical castration or other hormonal manipulation, e.g. GnRH agonists, GnRH antagonists, anti-androgens, oestrogens, 5α-reductase inhibitor). For patients that have received (neo)adjuvant ADT before radiotherapy, it should have been stopped for more than 1 year
  • Prior use of investigational agents that block androgen synthesis or block androgen receptor
  • Use of herbal products that may have hormonal anti-prostate cancer activity and/or are known to decrease PSA levels (e.g. saw palmetto)
  • Has received systemic glucocorticoids within 24 weeks prior to enrollment or is expected to require systemic glucocorticoids during the study period
  • Radiation therapy for treatment of the primary tumor within 3 months prior to enrollment
  • Use of an investigational agent within 4 weeks prior to enrollment is not allowed. The maximum allowed duration may be extended to comply with national regulations in the participating countries.
  • Gastrointestinal disorder affecting absorption (e.g. gastrectomy, active peptic ulcer disease within 3 months prior to enrollment)
  • Known hypersensitivity to the study treatment or any of its ingredients (refer to Investigator's brochure).
  • Severe or uncontrolled concurrent disease, infection or co-morbidity including active viral hepatitis, known human immunodeficiency virus infection with detectable viral load (Human immunodeficiency virus (HIV)) or chronic liver disease
  • History of prior malignancy. Adequately treated basal cell or squamous cell carcinoma of skin or superficial bladder cancer that has not spread behind the connective tissue layer (i.e. pTis, pTa, and pT1) is allowed, as well as any other cancer for which chemotherapy has been completed ≤ 5 years ago and from which the patient has been disease-free.
  • Clinically significant cardiovascular disease including:
  • Myocardial infarction within six months prior to randomization
  • Uncontrolled angina within 3 months prior to randomization
  • Coronary/peripheral artery bypass within 6 months prior to randomization
  • Stroke within 6 months prior to randomization
  • Congestive heart failure New York Heart Association (NYHA) class 3 or 4, or subjects with history of congestive heart failure NYHA class 3 or 4 in the past, unless a screening echocardiogram or multi-gated acquisition scan (MUGA) performed within 3 months results in a left ventricular ejection fraction that is ≥ 45%
  • History of clinically significant ventricular arrhythmias (e.g., ventricular tachycardia, ventricular fibrillation, torsades de pointes)
  • History of Mobitz II second degree or third degree heart block without a permanent pacemaker in place
  • Uncontrolled hypertension as indicated by a resting systolic blood pressure >170 mm Hg or diastolic blood pressure > 105 mm Hg at the screening visit

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02972060


Contacts
Layout table for location contacts
Contact: Evelien Nollet +3227741571 1532@eortc.be
Contact: Christophe Verstegen +3227741694 1532@eortc.be

Locations
Layout table for location information
Belgium
Hopitaux Universitaires Bordet-Erasme - Hopital Universitaire Erasme Recruiting
Brussels, Belgium, 1070
Contact: Thierry Roumeguere, Pr         
CHU Dinant Godinne - UCL Namur Recruiting
Yvoir, Belgium, 5530
Contact: Lionel D'Hondt, Pr         
Spain
Institut Catala d'Oncologia - ICO Badalona - Hospital Germans Trias i Pujol Recruiting
Badalona, Spain, 08916
Contact: Salvador Villa, Pr         
Hospital Universitario Ramon y Cajal Recruiting
Madrid, Spain, 28034
Contact: Fernando Lopez Campos, Pr         
Hospital Universitario Virgen De La Victoria Recruiting
Malaga, Spain, 29010
Contact: Bernardo Herrera, Pr         
Hospital Universitario de Salamanca Recruiting
Salamanca, Spain, 37007
Contact: Francisco Gomez Veiga, Pr         
Sponsors and Collaborators
European Organisation for Research and Treatment of Cancer - EORTC
Bayer
Investigators
Layout table for investigator information
Study Chair: Bertrand Tombal, Pr Cliniques universitaires saint-Luc (Brussels)

Layout table for additonal information
Responsible Party: European Organisation for Research and Treatment of Cancer - EORTC
ClinicalTrials.gov Identifier: NCT02972060     History of Changes
Other Study ID Numbers: EORTC-1532
2016-004334-17 ( EudraCT Number )
First Posted: November 23, 2016    Key Record Dates
Last Update Posted: April 25, 2018
Last Verified: April 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by European Organisation for Research and Treatment of Cancer - EORTC:
Hormone Naive Prostate Cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Androgens
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Genital Diseases, Male
Prostatic Diseases
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs